Does Somatostatin or Gastric Inhibitory Peptide Receptor Expression Correlate with Tumor Grade and Stage in Gut Neuroendocrine Tumors?

Publisher： Karger

E-ISSN： 1423-0194|101|1|45-57

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.101, Iss.1, 2015-01, pp. : 45-57

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

By  

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 220-226

Karger

Access to resources Recommend Favorite

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy

By  

Neuroendocrinology, Vol. 97, Iss. 1, 2012-01 ,pp. : 74-85

Karger

Access to resources Recommend Favorite

Gastric Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 16-19

Karger

Access to resources Recommend Favorite

Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?

By  

Neuroendocrinology, Vol. 103, Iss. 5, 2015-11 ,pp. : 560-566

Karger

Access to resources Recommend Favorite

Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 47-50

Karger

Access to resources Recommend Favorite